GlaxoSmithKline has withdrawn the US application for its restless legs syndrome treatment Solzira. The company, along with co-developer XenoPort, is …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

